Skip to content
Ymax®-ABL
Discovering revolutionized antibody therapeutics with fully human antibody library

Y-Biologics has established a premium quality of human antibody library, Ymax®-ABL, based on the phage display technique.
This finely optimized library with over 100 billion diversity accelerates to generate a bespoke therapeutic antibody for the target of interest.

ScFv-displayed phage and phagemid vector

Ymax®-ABL is a naïve cDNA library derived from B cells in normal human bone marrow,
therefore, it has proven its low toxicity, immunogenicity, and high productivity.
Ymax®-ABL
  • Single chain format (scFv) on phage
  • Properly shuffled heavy chain gene to maximize the antibody diversity
  • Improved helper phage system to optimize the scFv display
  • Animal protection
  • No need for Antibody Humanization
  • Re-construction of the library regularly to maintain its diversity and freshness
Ymax®-ABL confirmed by NGS
  • The diversity of Ymax®-ABL was analyzed and confirmed by next-generation DNA sequencing (NGS) in 2018 and it was verified that the most of germlines of VH and VL are included in this library.
  • Diversity: >1011 (VH : 2.35 x 108 / VL : 5.77 x 107)
The length distribution of CDR3 region

Fig. 1 Length VH of CDR3 : 5~25 aa

Fig. 2 Length of VL CDR3 : 8~12 aa

Ymax®-ABL confirmed by NGS

Ymax®-ABL contains most of VH germline families

Ymax®-ABL confirmed by NGS

Ymax®-ABL contains most of VL germline families

The diversity of amplified sequences at protein level
VH
VL
No. of total sequences used in analysis

8.20 x 105

2.05 x 106

ACE (Estimated number of unique characters)

2.79 x 108

5.77 x 107

Shannon’s index (Evenness of unique characters)
13.4972

14.1522

Highlights
Ymax®-ABL is a naïve cDNA library derived from B cells in normal human bone marrow,
therefore, it has proven its low toxicity, immunogenicity, and high productivity.
>0%
binder selection of conventional Ag
0Project
for monoclonal antibody generation
>0-9
binding affinity without optimization
0Years
Highly skilled experts with extensive experience
>0%
neutralizing Ab selection of conventional Ag
0Project
for bispecific antibody generation